SPRING1 and hepatocellular carcinoma: Notably, silencing of C12ORF49 rendered HCC cells more susceptible to Sorafenib treatment, underscoring the potential of C12ORF49 knockdown as a promising therapeutic strategy to improve the efficiency of Sorafenib in HCC therapy.